β-Arrestin1 Mediates the endocytosis and functions of macrophage migration inhibitory factor

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Xie, Lishi ^a,b   Qiao, Xiaohang ^a,b   Wu, Yanfang ^a   Tang, Jie ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; CD74 ANTIGEN; CHLORPROMAZINE; CYTOKINE; MACROPHAGE MIGRATION INHIBITORY FACTOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; BETA ARRESTIN; HLA ANTIGEN CLASS 2; MACROPHAGE MIGRATION INHIBITION FACTOR; RETINA S ANTIGEN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVATION; IMMUNOFLUORESCENCE TEST; MACROPHAGE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; HUMAN; IMMUNOLOGY; INVARIANT CHAIN; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ARRESTINS; CELL LINE; ENDOCYTOSIS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MAP KINASE SIGNALING SYSTEM; MICE;

EID: 79551510770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016428     Document Type: Article

References (39)

1. Bucala R, Donnelly SC (2007) Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 26: 281-285.
2. Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, et al. (2006) Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18: 688-703.
3. Mitchell RA, Metz CN, Peng T, Bucala R (1999) Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274: 18100-18106.
4. Shi X, Leng L, Wang T, Wang W, Du X, et al. (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25: 595-606.
5. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13: 587-596.
6. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, et al. (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197: 1467-1476.
7. Kleemann R, Grell M, Mischke R, Zimmermann G, Bernhagen J (2002) Receptor binding and cellular uptake studies of macrophage migration inhibitory factor (MIF): use of biologically active labeled MIF derivatives. J Interferon Cytokine Res 22: 351-363.
8. Dewire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) beta-Arrestins and Cell Signaling. Annu Rev Physiol 69: 483-510.
9. Lefkowitz RJ, Rajagopal K, Whalen EJ (2006) New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell 24: 643-652.
10. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, et al. (2000) betaarrestin- dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148: 1267-1281.
11. Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, et al. (2003) The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem 278: 6258-6267.
12. Le Roy C, Wrana JL (2005) Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 6: 112-126.
13. Wang LH, Rothberg KG, Anderson RG (1993) Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 123: 1107-1117.
14. Schnitzer JE, Oh P, Pinney E, Allard J (1994) Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J Cell Biol 127: 1217-1232.
15. McCormick PJ, Martina JA, Bonifacino JS (2005) Involvement of clathrin and AP-2 in the trafficking of MHC class II molecules to antigen-processing compartments. Proc Natl Acad Sci USA 102: 7910-7915.
16. Vrecl M, Anderson L, Hanyaloglu A, McGregor AM, Groarke AD, et al. (1998) Agonist-induced endocytosis and recycling of the gonadotropin-releasing hormone receptor: effect of beta-arrestin on internalization kinetics. Mol Endocrinol 12: 1818-1829.
17. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, et al. (1999) Betaarrestin- dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283: 655-661.
18. Meloche S, Seuwen K, Pages G, Pouyssegur J (1992) Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol Endocrinol 6: 845-854.
19. Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, et al. (2006) Continuous ERK Activation Downregulates Antiproliferative Genes throughout G1 Phase to Allow Cell-Cycle Progression. Current Biology 16: 1171-1182.
20. Lefkowitz RJ, Shenoy SK (2005) Transduction of receptor signals by betaarrestins. Science 308: 512-517.
21. George M, Vaughan JH (1962) In vitro cell migration as a model for delayed hypersensitivity. Proc Soc Exp Biol Med 111: 514-521.
22. Liao H, Bucala R, Mitchell RA (2003) Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). J Biol Chem 278: 76-81.
23. Swant JD, Rendon BE, Symons M, Mitchell RA (2005) Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J Biol Chem 280: 23066-23072.
24. Lue H, Thiele M, Franz J, Dahl E, Speckgens S, et al. (2007) Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26: 5046-5059.
25. Wadgaonkar R, Dudek SM, Zaiman AL, Linz-McGillem L, Verin AD, et al. (2005) Intracellular interaction of myosin light chain kinase with macrophage migration inhibition factor (MIF) in endothelium. J Cell Biochem 95: 849-858.
26. Schwartz V, Lue H, Kraemer S, Korbiel J, Krohn R, et al. (2009) A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett 583: 2749-2757.
27. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, et al. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122: 261-273.
28. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J (1996) Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271: 20608-20616.
29. Weber JD, Raben DM, Phillips PJ, Baldassare JJ (1997) Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J 326(Pt 1): 61-68.
30. Balmanno K, Cook SJ (1999) Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 18: 3085-3097.
31. Meyer-Siegler KL, Bellino MA, Tannenbaum M (2002) Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94: 1449-1456.
32. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, et al. (2005) Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 103: 588-598.
33. Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schuring MP, et al. (2003) Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 16: 491-504.
34. Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, et al. (1999) An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 5: 181-191.
35. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, et al. (2003) Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 93: 321-329.
36. Santos LL, Dacumos A, Yamana J, Sharma L, Morand EF (2008) Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: downregulation of ERK MAP kinase phosphorylation. Clin Exp Immunol 152: 372-380.
37. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, et al. (1994) Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33: 14144-14155.
38. Cooperstock MS (1974) Inactivation of endotoxin by polymyxin B. Antimicrob Agents Chemother 6: 422-425.
39. Liang W, Levchenko T, Khaw BA, Torchilin V (2004) ATP-containing immunoliposomes specific for cardiac myosin. Curr Drug Deliv 1: 1-7.